Emily K.
- Country
- Sweden
- Department
- Allergi- lung och CF-mottagningen barn
Research Overview
- A Phase 2a Study to Evaluate the Safety and Efficacy of ABBV-142 in Adults with Idiopathic Pulmonary Fibrosis
- Phase 2 Randomized Double‑Blind Study of VX-828/Deutivacaftor With and Without Tezacaftor in Adults with Cystic Fibrosis
- Evaluation of Long-term Safety and Efficacy of Tezacaftor, Deutivacaftor, and Vanzacaftor Combination Therapy in Patients with Cystic Fibrosis
Data & Insights
Has run more than one trial at 37 of 126 partner sites.
Specializations
Respiratory Medicine
The investigator specializes in the treatment and management of cystic fibrosis, focusing on advanced therapeutic approaches for this genetic disorder.
- Genetic Respiratory Disorders
- Pulmonary Function Management
- Long-term Disease Management
Primary interest in evaluating innovative combination therapies for improving respiratory function in cystic fibrosis patients.
Therapeutic Innovation
Active involvement in investigating novel combination therapy approaches for treating genetic respiratory conditions.
- Multi-component Treatment Strategies
- Treatment Safety Assessment
- Long-term Clinical Outcomes
Expertise in evaluating the safety and tolerability profiles of advanced therapeutic combinations.
Clinical Management
Focuses on developing comprehensive treatment protocols for chronic genetic conditions affecting the respiratory system.
- Patient Safety Monitoring
- Therapeutic Response Assessment
- Long-term Patient Care
Specializes in evaluating treatment efficacy and patient outcomes in chronic respiratory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.